AMRI

William S. Marth Joins CONTINUUS Pharmaceuticals Board of Directors, Bringing Commercial Leadership and Manufacturing Expertise to the Company

Retrieved on: 
Wednesday, February 21, 2024
Biotechnology, Manufacturing, Other Manufacturing, Health, Pharmaceutical, AMRI, MBA, CGMP

His deep understanding of the industry is pivotal in ensuring a successful cGMP commercial implementation of CONTINUUS technology and makes him an ideal addition to CONTINUUS’s leadership team.

Key Points: 
  • His deep understanding of the industry is pivotal in ensuring a successful cGMP commercial implementation of CONTINUUS technology and makes him an ideal addition to CONTINUUS’s leadership team.
  • "It is an exciting opportunity to join the Board of CONTINUUS, a leader in integrated continuous manufacturing of pharmaceuticals.
  • Continuous manufacturing is an important strategic initiative for the pharmaceutical industry and robustness of global supply chains," said Mr. Marth.
  • A Director of the company since 2012, Mr. Marth served as President and Chief Executive Officer of AMRI since 2014.

Resilience Appoints Bill Marth as President of Services

Retrieved on: 
Tuesday, November 7, 2023
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, Sale, GTCR, MBA, National Resilience Institute, Multimedia, AMRI, Patient, Management, Resilience

National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that William S. Marth, RPh., MBA has been appointed to the newly created role of President of Services.

Key Points: 
  • National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that William S. Marth, RPh., MBA has been appointed to the newly created role of President of Services.
  • View the full release here: https://www.businesswire.com/news/home/20231107738739/en/
    In this role, Mr. Marth will have end-to-end responsibility for all development and manufacturing services and commercial activities at Resilience.
  • Resilience’s objective in creating the new Services organization is to strengthen the company’s focus on providing the highest quality execution for pre-clinical, clinical and commercial programs.
  • “We look forward to benefitting from his experience and capability to better serve our customers and further scale Resilience.”

Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

Retrieved on: 
Thursday, June 29, 2023
Science, Drug discovery, Health care, Frost, AMRI, Pharmaceutical industry

ALBANY, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan.

Key Points: 
  • ALBANY, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan.
  • “Curia has built its reputation by offering a best-in-class customer ownership and service experience.
  • The company surveys clients to gauge their overall satisfaction and ensure that it is upholding the highest standards,” said Unmesh Lal, director, Healthcare & Life Sciences, Frost & Sullivan.
  • Each year, Frost & Sullivan employs a rigorous evaluation, measuring business and customer impact, to identify companies that consistently innovate to meet their customers’ needs while navigating new challenges and opportunities.

Kindeva Drug Delivery Announces the Appointment of David Stevens as Global CCO

Retrieved on: 
Wednesday, April 5, 2023
Science, Other Science, Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Other Health, GMP, Charles River Laboratories, University, Drug delivery, Marketing, MBA, Research, Multimedia, CCO, CDMO, Patient, Recipharm, Growth, AMRI, Fine chemical, Kindeva

Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced that David Stevens has joined the organization as global chief commercial officer (CCO).

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced that David Stevens has joined the organization as global chief commercial officer (CCO).
  • Stevens will spearhead the commercial, business development, and research and development activities for the business to ensure continued growth, expansion, and innovation.
  • View the full release here: https://www.businesswire.com/news/home/20230405005276/en/
    David Stevens has been appointed global chief commercial officer for Kindeva Drug Delivery.
  • “The Kindeva organization has a strong history of achievement, expertise, and the infrastructure to handle an extensive range of critical complex drug delivery challenges,” Stevens said.

Phosphorex Expands Leadership Team: Appoints David Tammaro as Chief Financial Officer

Retrieved on: 
Tuesday, January 17, 2023
CDMO, Analysis, Finance, AMRI, R, CGMP, Knowledge, Management, Interior design

HOPKINTON, Mass., Jan. 17, 2023 /PRNewswire/ -- Phosphorex, an Ampersand Capital Partners company, and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today the appointment of David Tammaro as Chief Financial Officer.

Key Points: 
  • HOPKINTON, Mass., Jan. 17, 2023 /PRNewswire/ -- Phosphorex, an Ampersand Capital Partners company, and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today the appointment of David Tammaro as Chief Financial Officer.
  • David brings over 15 years of financial leadership experience and will lead all aspects of financial and administrative planning to support and enable the company's high growth plan.
  • Prior to joining Phosphorex, David served as a consultant, working with senior leadership teams on the development and improvement of financial planning & analysis systems and processes, as well as cGMP facility buildouts.
  • On behalf of the entire Phosphorex team, I welcome David and look forward to his contributions."

Computer-Aided Drug Discovery Global Market Report 2022: Artificial Intelligence and Big Data to Reshape Sector Moving Forward - ResearchAndMarkets.com

Retrieved on: 
Friday, November 11, 2022
Health Technology, Pharmaceutical, Health, United Nations, CVD, AstraZeneca, Charles River Laboratories, Drug design, Prevalence, AMRI, Artificial intelligence, Premier, Inc., WHO, Cardiovascular disease, Neurology, Conditional sentence, Respiratory disease, Research, World, Patient, CAGR, Diabetes, Laboratory, Biotechnology, First Nations in Ontario, COVID-19, Intelligence, Polypharmacology, UN, Bayer, Drug discovery, World Health Organization, Public health, Medical device, Pharmaceutical industry, Fine chemical

Also, lower product penetration in the emerging economies is also restraining the global computer-aided drug discovery market.

Key Points: 
  • Also, lower product penetration in the emerging economies is also restraining the global computer-aided drug discovery market.
  • Emerging concepts such as artificial intelligence (AI) and big data in computer-aided drug discovery, on the other hand, may drive the market over the forecast period.
  • Many aspects of drug discovery can benefit from artificial intelligence, including drug design, chemical synthesis, drug screening, drug repurposing, and polypharmacology.
  • The global computer-aided drug discovery market is segmented on the basis of type, therapeutic area, end-user, and region.

The Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, claims InsightAce Analytic

Retrieved on: 
Tuesday, November 1, 2022
RNA transfection, Solid lipid nanoparticle, RNA, SaRNA, Development, Emergent, CMO, CMOS, BioNTech, MicroRNA, LNP, Plasmid, Merck, Diosynth, CGMP, Nucleic acid, Organization, Clinical trial, Research, Operation Warp Speed, Oncology, PTS, Merck Group, COVID-19, Commercial, AMRI, CDMO, Safety, CAGR, Technology, Viral Research and Diagnostic Laboratories, Vaccine, SM-102, Partnership, LPN, International, Nanoparticle, Prevalence, Contract, Drug development, FDB, Industry, Attention, Fine chemical, Pharmaceutical industry, Others

According to the latest research by InsightAce Analytic, the global lipid nanoparticles (LNPs) CDMO market is expected to exhibit a CAGR of 13.8% during the forecast period of 2022-2030.

Key Points: 
  • According to the latest research by InsightAce Analytic, the global lipid nanoparticles (LNPs) CDMO market is expected to exhibit a CAGR of 13.8% during the forecast period of 2022-2030.
  • This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles (LNPs) CDMO services in the coming years.
  • Lipid nanoparticles (LPNs) are at the forefront of nanotechnology's rapid development, with numerous potential uses in drug delivery and research.
  • Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs), by Product, 2020-2030 (Value US$ Mn)

The Lipid Nanoparticles (LNPs) CDMO Market is Projected to Grow at a CAGR of 13.8%, During the Period 2022-2030, claims InsightAce Analytic

Retrieved on: 
Tuesday, November 1, 2022
RNA, Emergent, Nucleic acid, Organization, Research, COVID-19, LNP, SM-102, LPN, Drug development, Solid lipid nanoparticle, Development, Plasmid, Merck, Partnership, PTS, Oncology, Merck Group, Commercial, Safety, Technology, Viral Research and Diagnostic Laboratories, International, Nanoparticle, Prevalence, SaRNA, CMO, CMOS, BioNTech, MicroRNA, Diosynth, Clinical trial, AMRI, CDMO, Attention, RNA transfection, CGMP, Operation Warp Speed, Vaccine, Contract, FDB, Industry, Fine chemical, Pharmaceutical industry, Others

This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles(LNPs) CDMOservices in the coming years.

Key Points: 
  • This increase in outsourcing is projected to fuel the business of Lipid Nanoparticles(LNPs) CDMOservices in the coming years.
  • Lipid nanoparticles (LPNs) are at the forefront of nanotechnology's rapid development, with numerous potential uses in drug delivery and research.
  • Lipid nanoparticles provide the prospect of developing new therapies due to their unique size dependent features.
  • Global Lipid Nanoparticles (LNPs) CDMO Market (Nucleic Acids LNPs), by Product, 2020-2030 (Value US$ Mn)

WILLOW BIOSCIENCES PROVIDES CBG UPDATE

Retrieved on: 
Wednesday, August 31, 2022
COVID-19, AB, AMRI, Food, Willow Springs Distilling Company, Research, Hand, View, Government, Protein, DSP, Generally recognized as safe, Technology transfer, Interim, Risk, WLLW, TSX, Patent, Willow Garage, Multimedia, MSA, CDMO, Company, Certification, Contract, News, Failure, Fermentation, GRAS, Intellectual property, Cannabinoid, Industry, Health, Forward-looking statement, CBG, Fine chemical, Willow

CALGARY, AB and MOUNTAIN VIEW, Calif, Aug. 31, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX:WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to provide an update on cannabigerol ("CBG"), the Company's first commercialized functional ingredient in its portfolio.

Key Points: 
  • CALGARY, AB and MOUNTAIN VIEW, Calif, Aug. 31, 2022 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX:WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to provide an update on cannabigerol ("CBG"), the Company's first commercialized functional ingredient in its portfolio.
  • As the market for biosynthetically produced CBG continues to develop, Willow will be in a strong position to deliver commercial scale volumes.
  • When the regulatory environment permits, Willow is also well-positioned to develop additional cannabinoids beyond CBG.
  • Willow previously announced that it had successfully completed the initial toxicological assessment for Generally Recognized as Safe ("GRAS") for its FutureGrown CBG product.

Curia Appoints Niall Condon to Lead Manufacturing

Retrieved on: 
Tuesday, August 2, 2022
Biotechnology, Supply Chain Management, Manufacturing, Professional Services, Health, Pharmaceutical, Venture Capital, Research, Other Manufacturing, Retail, Science, AMRI, Hazira Manufacturing Division, R, Industry, CEO, Solution, Chemical engineering, Head, Munster Technological University, Multimedia, Approved Drug Products with Therapeutic Equivalence Evaluations, CDMO, Business administration, Manufacturing, Pfizer, Master of Business Administration, Patient, Condon, Growth, API, Rensselaer Polytechnic Institute, OSD, Fine chemical, Mylan, Science

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced the appointment of Niall Condon as president of its Manufacturing Division, with immediate effect.

Key Points: 
  • Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced the appointment of Niall Condon as president of its Manufacturing Division, with immediate effect.
  • Condon will drive growth and be responsible for operational delivery of Curias commercial manufacturing services and products, including API and Drug Product.
  • (Photo: Business Wire)
    Im very pleased to welcome Niall to Curia at this critical point in our growth journey, said Curia Chairman and CEO John Ratliff.
  • Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers.